Johnson & Johnson (JNJ): Price and Financial Metrics
Johnson & Johnson (JNJ)
Today's Latest Price: $160.30 USD
Updated Jan 15 7:00pm
Add JNJ to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
Ranked of 239 in Medical - Pharmaceuticals
See all "A" rated Strong Buy stocks
JNJ Stock Summary
- With a market capitalization of $422,917,980,257, Johnson & Johnson has a greater market value than 99.77% of US stocks.
- Johnson & Johnson's stock had its IPO on January 1, 1986, making it an older stock than 92.8% of US equities in our set.
- The volatility of Johnson & Johnson's share price is greater than that of just 0.18% US stocks with at least 200 days of trading history.
- If you're looking for stocks that are quantitatively similar to Johnson & Johnson, a group of peers worth examining would be WMT, JPM, V, PG, and UNH.
- JNJ's SEC filings can be seen here. And to visit Johnson & Johnson's official web site, go to www.jnj.com.
JNJ Stock Price Chart Interactive Chart >
JNJ Price/Volume Stats
| Current price | $160.30 | 52-week high | $161.95 |
| Prev. close | $160.65 | 52-week low | $109.16 |
| Day low | $159.10 | Volume | 7,630,800 |
| Day high | $161.40 | Avg. volume | 8,384,970 |
| 50-day MA | $151.13 | Dividend yield | 2.52% |
| 200-day MA | $147.79 | Market Cap | 422.00B |
Johnson & Johnson (JNJ) Company Bio
Johnson & Johnson researches and develops, manufactures, and sells various products in the health-care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. Some of its well-known brands include Tylenol-fever, Listerine-bad breath, Splenda-no-calorie sweetener, Neutrogena-skin care, Pepcid-heartburn, Zyrtec - allergy, Motrin-ibuprofen, Sudafed-allergy, and plenty more. The company was founded in 1885 and is based in New Brunswick, New Jersey.
JNJ Price Forecast Based on DCF Valuation
| Current Price | DCF Fair Value Target: | Forecasted Gain: |
| $160.30 | $64.67 | -60% |
The table below illustrates the output of a discounted cash flow forecast using a variety of scenarios for Johnson & Johnson. To summarize, we found that Johnson & Johnson ranked in the 31th percentile in terms of potential gain offered. We should note, though, that all scenearios modelled for this stock suggest it is overvalued. As for the metrics that stood out in our discounted cash flow analysis of Johnson & Johnson, consider:
- The company has produced more trailing twelve month cash flow than 97.59% of its sector Healthcare.
- The business' balance sheet reveals debt to be 8% of the company's capital (with equity being the remaining amount). Approximately just 22.84% of US stocks with free cash flow have a lower reliance on debt in their capital structure.
- JNJ's estimated cost of debt, based largely on its market capitalization and its interest coverage ratio, is 3%; for context, that number is higher than 37.74% of tickers in our DCF set.
| Terminal Growth Rate in Free Cash Flow | Return Relative to Current Share Price |
| 0% | -60% |
| 1% | -60% |
| 2% | -60% |
| 3% | -59% |
| 4% | -59% |
| 5% | -58% |
Want more companies with a valuation profile/forecast similar to that of Johnson & Johnson? See BAX, ICLR, BIO, HOLX, and LNTH.
Loading social stream, please wait...